Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for Parkinson's disease.

Huddleston DE, Factor SA.

Curr Neurol Neurosci Rep. 2011 Aug;11(4):345-8. doi: 10.1007/s11910-011-0206-y. No abstract available.

A neuroprotective role for angiogenin in models of Parkinson's disease.

Steidinger TU, Standaert DG, Yacoubian TA.

J Neurochem. 2011 Feb;116(3):334-41. doi: 10.1111/j.1471-4159.2010.07112.x.

Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.

Booij J, Berendse HW.

J Neurol Sci. 2011 Nov 15;310(1-2):40-3. doi: 10.1016/j.jns.2011.07.029. Review.

Measurement of patient-centered outcomes in Parkinson's disease: what do patients really want from their treatment?

Nisenzon AN, Robinson ME, Bowers D, Banou E, Malaty I, Okun MS.

Parkinsonism Relat Disord. 2011 Feb;17(2):89-94. doi: 10.1016/j.parkreldis.2010.09.005.

Reorganization of motor system in Parkinson's disease.

Kalmar Z, Kovacs N, Perlaki G, Nagy F, Aschermann Z, Kerekes Z, Kaszas B, Balas I, Orsi G, Komoly S, Schwarcz A, Janszky J.

Eur Neurol. 2011;66(4):220-6. doi: 10.1159/000330658.

The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM.

Mov Disord. 2011 Jun;26(7):1225-33. doi: 10.1002/mds.23631.

Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model.

Choi WS, Palmiter RD, Xia Z.

J Cell Biol. 2011 Mar 7;192(5):873-82. doi: 10.1083/jcb.201009132.

Diurnal salivary cortisol concentrations in Parkinson's disease: increased total secretion and morning cortisol concentrations.

Skogar O, Fall PA, Hallgren G, Lökk J, Bringer B, Carlsson M, Lennartsson U, Sandbjork H, Törnhage CJ.

Int J Gen Med. 2011;4:561-9. doi: 10.2147/IJGM.S20875.

[Association of PARK 16 polymorphisms with Parkinson's disease in Han population of Suzhou area].

Li DH, Wang J, Mao CJ, Hu WD, Xiao L, Yang YP, Qin ZH, Liu CF.

Zhonghua Yi Xue Za Zhi. 2011 Feb 1;91(5):296-300. Chinese.

Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).

Reid WG, Hely MA, Morris JG, Loy C, Halliday GM.

J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):1033-7. doi: 10.1136/jnnp.2010.232678.

Functional MRI of impaired finger dexterity in Parkinson's disease.

Bohlhalter S, Abela E, Hallett M.

Exp Neurol. 2011 Jan;227(1):24-5. doi: 10.1016/j.expneurol.2010.11.006. No abstract available.

A microfluidic-based neurotoxin concentration gradient for the generation of an in vitro model of Parkinson's disease.

Seidi A, Kaji H, Annabi N, Ostrovidov S, Ramalingam M, Khademhosseini A.

Biomicrofluidics. 2011 Jun;5(2):22214. doi: 10.1063/1.3580756.

Parkinson's: treating the symptoms.

Lindahl DA.

Br J Nurs. 2011 Jul 28-Aug 4;20(14):852, 854-7.

Parkinson's disease: news on tremor, subthalamic stimulation and impulse control disorders.

Strupp M.

J Neurol. 2011 Feb;258(2):340-2. doi: 10.1007/s00415-011-5916-1. No abstract available.

Association study between the LINGO1 gene and Parkinson's disease in the Italian population.

Annesi F, De Marco EV, Rocca FE, Nicoletti A, Pugliese P, Nicoletti G, Arabia G, Tarantino P, De Mari M, Lamberti P, Gallerini S, Marconi R, Epifanio A, Morgante L, Cozzolino A, Barone P, Torchia G, Z

Parkinsonism Relat Disord. 2011 Sep;17(8):638-41. doi: 10.1016/j.parkreldis.2011.06.020.